TokenPost·
Rezolute Reports 13 of 16 Patients Achieved at Least 50% Glucose Infusion Rate Reduction
The Phase 3 upLIFT study is evaluating ersodetug for tumor hyperinsulinism.
More news
- TokenPostTON Strategy Sold 2 Million Gram Tokens for $2.32 Million
- TokenPostVertex Resource Group Q3 Gross Revenue Rises 5.7% to C$57.14 Million
- Crypto BriefingMarvell brings AI memory and interconnect tech to SC26 in Chicago
- TokenPostAudaCity Logs the Sharpest Loss as Seppuku Leads Crypto Searches
- crypto.newsBitcoin price falls 4%, can BTC recover above $70,000?
- TokenPostDark Defender Marks XRP (XRP) Wave 2 Low at $0.9852 in Reversal Setup